UK Parliament Backbench Debate: Is WHO Really Doing Good for Human Health?

Special Report by Charlotte Yu
Jan.19.2024
UK Parliament Backbench Debate: Is WHO Really Doing Good for Human Health?
Without tax (price) incentives and flavor differentiation compared to traditional cigarettes, there would be little motivation for people to quit smoking.

A backbench debate was held on Jan 18 in the UK Parliament as the tenth session of the Conference of the Parties to the Framework Convention on Tobacco Control (COP10) is scheduled to take place in Panama from February 5 to 10, and the UK will be sending a delegation.

 

The debate, initiated by Members of Parliament Andrew Lewer, Mr. Virendra Sharma, and Martyn Day, aimed to challenge the WHO's opposition to e-cigarettes, focusing on the regulation of e-cigarettes in the UK, the World Health Organization (WHO), and the differing stances of the organization and the UK government on e-cigarettes.

 

The WHO for a long time has been committed to controlling the use of tobacco and nicotine products, particularly e-cigarettes. According to reports from December 14, 2023, the organization emphasized the need for urgent action to control e-cigarettes, aiming to protect children and non-smokers while minimizing health risks to the public. The WHO pointed out that the nicotine present in e-cigarettes is highly addictive and harmful to health.

 

During the debate on Thursday, Member of Parliament Andrew Lewer argued against this perspective. He cited research from Cancer Research UK, stating that "it's not nicotine but the chemicals produced during the combustion of tobacco that cause lung cancer."

 

Based on this theoretical finding, MP Andrew Lewer throughout the debate addressed vaporized e-cigarettes as "tobacco harm reduction products," aligning with the broader direction of the UK government's tobacco control policy. He insisted on two central arguments. First, new tobacco products, including vaporized e-cigarettes, should not be subject to the same tax rates as traditional cigarettes. Second, flavored vaporized e-cigarettes should not be banned. He argued that without tax (price) incentives and flavor differentiation compared to traditional cigarettes, there would be little motivation for people to quit smoking.

 

UK Parliament Backbench Debate: Is WHO Really Doing Good for Human Health?
Andrew Lewer, a member of parliament who spoke in the backbench debate on January 18th | Image source: 2FIRSTS

 

In addition to urging the UK delegation to maintain its stance on the smoking cessation role of e-cigarettes in international conferences, Andrew Lewer also questioned the entire WHO institution during the debate and raised the issue of whether the UK should review the scale of its donations to the organization. This is because the UK is currently one of the largest funders of the WHO, and there is a need to ensure that "taxpayers' money is well utilized."

 

Later in the debate, co-initiator Virendra Sharma stated, "COP10 and WHO should not make it harder for those who want to quit smoking with e-cigarettes." Therefore, policies that excessively regulate e-cigarettes, heated tobacco, and oral nicotine pouches are worthy of debate.

 

He also mentioned that although the UK is a global leader in tobacco harm reduction policies, it can still learn from other countries' successful experiences in using new nicotine products to control smoking. He cited Japan and Sweden as examples where heated tobacco and oral snus significantly reduced smoking rates. There are better ways for the UK to achieve a better outcome through compromise.

 

Labour politician and Member of Parliament for Bristol South, Karin Marguerite Smyth, also participated in the debate. After expressing anticipation for the UK delegation's participation in the treaty conference and conveying the country's voice, she mentioned that many MPs have received letters from constituents inquiring about e-cigarettes and smoking because it will be a central topic at COP10. Voters are concerned about whether this conference will change the future use of e-cigarettes by British citizens. She asked the Minister of Public Health if there are plans to include other nicotine products in the upcoming government bill's regulatory process.

 

UK Parliament Backbench Debate: Is WHO Really Doing Good for Human Health?
Virendra Sharma | Image source: 2FIRSTS

 

The responsibility of responding to inquiries in this debate fell on Dame Andrea Jacqueline Leadsom, who has taken office as the Deputy Minister of Public Health, Start for Life, and Primary Care since November 2023. She expressed opposing views to some points raised by the aforementioned MPs.

 

Using her own experience of teenage smoking and the challenging process of quitting, she stated that claiming nicotine is entirely harmless is "wrong" and reiterated the addictive nature of nicotine. She also raised some questions, mentioning that flavors like cherryade and bubble-gum are not designed for adults. These flavors and packaging resembling little Coke bottles or brightly colored like bubble-gum are clearly "aimed at children." The fact that e-cigarettes are placed next to candies, sold conveniently at pocket-money prices is concerning. Therefore, she urged MPs not to "naively look at this issue" and emphasized that only strong enforcement measures can ensure that e-cigarettes are not sold to minors.

 

UK Parliament Backbench Debate: Is WHO Really Doing Good for Human Health?
Dame Andrea Jacqueline Leadsom who spoke in the back seat debate on January 18th | Image source: 2FIRSTS

 

Regarding the upcoming COP10, she described the UK as a "unique case" on the issue of e-cigarettes and stated that the country will present its position at the conference, emphasizing that e-cigarettes are a crucial tool to help adults quit smoking. "But as for whether there should be a change in the current level of donations to the WHO, the UK government tends to maintain the existing level." She concluded by stating that she will provide a statement to the Parliament after COP10 to update on the proceedings.

 

E-cigarettes in Backbench Debates

 

This is not the first time tobacco (or novel tobacco) has appeared in backbench debates in the UK.

 

Backbench debates, also known as Westminster Hall debates, allow MPs to raise local or national issues and receive responses from government ministers.

 

According to incomplete statistics, in June 2020, government MPs revolted against the ban on people importing liquid nicotine for e-cigarettes; on November 3, 2022, the House of Commons debated the Independent Review of Smokefree 2030 policies; and earlier this week, there was another debate on e-cigarettes. On January 16, a debate hosted by Conservative MP Peter Gibson discussed issues related to illicit (gray) market vaping products and underage illegal vaping.

 

The UK's stance on novel tobacco, especially e-cigarettes, has consistently differed from the WHO's perspective. The UK government has been supportive of e-cigarettes as an alternative to reduce the harm of smoking. According to the UK government's viewpoint, e-cigarettes can help smokers quit, and their harm is much lower than that of traditional tobacco products.

 

A report from Policy Exchange indicates that smoking has a significant impact on the economy, and reducing smoking rates not only improves health conditions and alleviates the burden on the national health service but also promotes productivity and economic growth.

 

2FIRSTS will continue to monitor the upcoming Conference of the Parties to the WHO Framework Convention on Tobacco Control (COP10) in Panama, as well as developments in UK tobacco control policies and regulations for both traditional and novel tobacco products.

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

BofA: U.S. Nicotine Market Splits as Vapor Sales Fall 17.2% and Oral Tobacco Rises 5.8%
BofA: U.S. Nicotine Market Splits as Vapor Sales Fall 17.2% and Oral Tobacco Rises 5.8%
According to Investing.com citing Bank of America scanner data for the four weeks ending May 30, U.S. nicotine category performance was mixed, with cigarette, vapor and cigar sales declining while oral tobacco sales rose 5.8%.
Jun.10
Special Report | Russian Vape Compromise Faces First Hurdles
Special Report | Russian Vape Compromise Faces First Hurdles
Russia’s regional vape-ban model is facing early legal and political tests, as Perm Krai moves ahead before federal legislation is fully adopted. The case highlights uncertainty over regional authority, concerns from business groups about market fragmentation, and the risk that pressure against regional bans could revive calls for a stricter nationwide prohibition.
Industry Insight
May.28
Imperial Brands Launches 2ml+10ml blu MAX 6000 Vape System
Imperial Brands Launches 2ml+10ml blu MAX 6000 Vape System
mperial Brands has launched blu MAX 6000 in the UK, positioning the product as a higher-puff vape kit with longer-lasting use and replaceable pod+refill options. The device uses a 2ml+10ml click-on box format, with starter kits priced at £10.99 (approximately $14) and replacement pod+refill packs priced at £7.99 (approximately $10).
Market
May.19
Imperial Tobacco Canada Responds to Anti-Smoking Groups on Youth Vaping
Imperial Tobacco Canada Responds to Anti-Smoking Groups on Youth Vaping
Imperial Tobacco Canada responded to the April 17 press conference by anti-smoking groups by calling for a more focused, fact-based discussion on youth vaping that targets the illicit market. The company said youth should not be using nicotine products and that it supports strong measures to prevent youth access, but argued that the discussion failed to clearly distinguish between the regulated market and the illicit market that is driving youth access.
Apr.22 by 2FIRSTS.ai
State Registries Are Reshaping U.S. Vape Market Access 2Firsts Interview with U.S. Vapor Manufacturers Association President Allison Boughner
State Registries Are Reshaping U.S. Vape Market Access 2Firsts Interview with U.S. Vapor Manufacturers Association President Allison Boughner
As the U.S. vapor market faces FDA authorizations, import seizures and growing state-level restrictions, AVM President Allison Boughner told 2Firsts that state product registries and white-list systems are having the most immediate impact. She said distributors are placing greater weight on documentation, product origin and supply-chain transparency.
Special Report
May.26
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Summary Ispire Technology announced a strategic joint venture with Chinese pharmaceutical company Jincheng Pharma to manufacture and commercialize nicotine pouch products. The partnership combines pharmaceutical-grade production capabilities with Ispire’s global regulatory infrastructure and distribution network as the company expands beyond vaping hardware into oral nicotine products.
Business
May.13